Instruction 1(b).

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, I	D.C. 20549
---------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

5 Polationship of Poporting Porcon(s) to Issuer

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person ADAMS R MARK					Adaptive Biotechnologies Corp [ADPT]									(Chec	k all applicable) Director Officer (give title		ig i eis	10% Ov	vner		
(Last) 1165 EA	(Fir	,	Middle)			3. Date of Earliest Transaction (Month/Day/Year) 01/09/2023								X	below	Officer (give title Other (specify below) Chief Operating Officer					
(Street) SEATTL (City)			8109 Zip)		4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Ind Line) X	Form Form	idual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Table	I - Noi	n-Deriva	tive S	Secu	rities	Acq	uired,	Dis	posed of	, or E	Benefi	iciall	y Own	ed					
1. Title of Security (Instr. 3)				2. Transaction Date (Month/Day/Year)		Exe if an	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (ADisposed Of (D) (Instr. 3, 5)				Securit Benefic Owned	Amount of ecurities eneficially wned Following eported		Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	v	Amount	(A) (D)	or Pr	ice	Transaction(s) (Instr. 3 and 4)				(111511. 4)				
Common Stock 01/09						2023			S ⁽¹⁾		995	Г) [\$8.5	11	5,648		D			
Common Stock 01/1				01/10/	2023			S ⁽²⁾		2,130	Г	\$	8.58	11	3,518		D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																				
1. Title of Derivative Security (Instr. 3)	rative Conversion Date Execution Date rity or Exercise (Month/Day/Year) if any			on Date,	Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y C	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership t (Instr. 4)		
					Code		(A) (D)		Date Exercisable		Expiration Date	Numb of Title Share									

Explanation of Responses:

Remarks:

/s/ R. Mark Adams by Eric Billings, attorney-in-fact

01/11/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.

^{2.} The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2022.